Nabriva's pneumonia drug succeeds in late-stage trial, shares soar

(Reuters) - Nabriva Therapeutics Plc shares more than doubled in premarket trading on Monday after the company said its experimental antibiotic for community-acquired bacterial pneumonia met the main goal of a late-stage study.